Price
No data yet.
Social Signal Score
Revenue
$11.38M-5.85%Company Profile
- CEO
- Joseph Vincent Amato
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.76
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.05
Financials
Revenue
$11.38M-5.8%Net Income
$4.02M+30.5%EBITDA
$6.67M+116.7%Free Cash Flow
$4.90M+53.5%EPS (diluted)
$0.05-80.0%Shares Outstanding (diluted)
80.39M+556.8%Operating Expenses
$0.00Cash & Debt
$4.58MReturn of Capital
$16.88MDividend per Share
$0.09Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $26.72M | $20.22M | $0.66 |
| 2024 | $41.75M | $37.94M | $1.44 |
| 2023 | $22.35M | $3.72M | $0.14 |
| 2022 | $9.53M | $-33.49M | $-0.86 |
| 2021 | $29.51M | $26.80M | $0.69 |
| 2020 | $9.17M | $3.02M | $0.08 |
| 2019 | $25.51M | $22.53M | $1.15 |
| 2018 | $-834.7K | $-3.09M | $-0.16 |
| 2017 | $25.82M | $23.87M | $1.22 |
| 2016 | $29.24M | $27.36M | $1.40 |
| 2015 | $25.25M | $-14.23M | $-0.73 |
| 2014 | $27.02M | $16.16M | $0.83 |
| 2013 | $27.33M | $33.63M | $1.72 |
| 2012 | $27.51M | $41.86M | $2.14 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NHS's reported EPS growth of -8.7% a year over 13 years.
- EPS in 5 years
- $0.42
- Implied price
- $4.61
- Return from $5.41
- -3.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.29 — -57.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| -18.7% | -21.2% | -17.2% | -13.8% | -10.8% | -8.3% |
| -13.7% | -16.4% | -12.1% | -8.5% | -5.4% | -2.6% |
| -8.7% | -11.5% | -7.0% | -3.2% | 0.1% | 3.0% |
| -3.7% | -6.7% | -1.9% | 2.1% | 5.6% | 8.7% |
| 1.3% | -1.8% | 3.2% | 7.4% | 11.1% | 14.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (6)
- Newsprnewswire.com·15d ago·Neutral
NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock.
View source ↗ - Newsproactiveinvestors.com·16d ago·Positive
Ondine shares backed by Peel Hunt as NHS ICU access expands Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has won support from Peel Hunt after partnering with Mela Solutions to accelerate access for its Steriwave infection-prevention technology across NHS intensive care units. Peel Hunt retained its ‘buy' rating and 29p price target, highlighting the potential for the collaboration to generate trust-specific evidence on Steriwave's clinical and economic benefits.
View source ↗ - Newsproactiveinvestors.com·17d ago·Neutral
Ondine Biomedical taps NHS intensive care data to prove Steriwave pays its way Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has teamed up with Mela Solutions, whose software sits in 90% of NHS intensive care units, to help hospitals test whether its Steriwave system saves them money. Steriwave uses light to activate an antimicrobial treatment applied inside the nose, killing bacteria that can cause infections in hospital patients.
View source ↗ - Newsseekingalpha.com·26d ago·Negative
NHS: The High Yield Is Not A Reason To Own This Fund (Rating Downgrade) The Neuberger High Yield Strategies Fund offers a 19.15% yield but struggles to cover its distribution, risking net asset value destruction. NHS is almost entirely allocated to fixed-rate high-yield bonds, making it vulnerable in a rising rate and inflationary environment. Despite trading at an 11.13% discount to NAV, NHS has underperformed junk bond indices and is not earning enough to justify its payout.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on September 30, 2026, has a record date of September 15, 2026, and has an ex-date of September 15, 2026.
View source ↗ - Newsprnewswire.com·49d ago·Negative
Neuberger High Yield Strategies Fund Announces Increase in Leverage NEW YORK, Aug. 27, 2026 /PRNewswire/ -- High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") announced today that its Board of Directors has approved a $25 million increase in the committed debt financing available under its revolving debt financing facility ("Revolving Loan Facility") with a major unaffiliated financial institution, as well as the issuance of $10 million in additional Mandatory Redeemable Preferred…
View source ↗
Insider trading
Open-market buys and sells by NHS officers and directors.
- Bought
- $702250.1bn
- Sold
- $1.2m
55 trades
1 trade
- Kocinski Chrisbought
- Kocinski Chrisbought
- Lind Josephbought
- Lind Josephbought
- Metlife Investment Management, Llcbought
- Saba Capital Management, L.p.sold
- Metlife Investment Management, Llcbought
- Metlife Investment Management, Llcbought
44 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NHS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.